高级检索
当前位置: 首页 > 详情页

Executive Summary: Clinical Practice Guideline of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD) in China

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Nanjing Gen Hosp, Natl Clin Res Ctr Kidney Dis, Dept Nephrol, Nanjing 210002, Jiangsu, Peoples R China [2]Univ Elect Sci, Sichuan Acad Med Sci, Sch Med, Chengdu, Sichuan, Peoples R China [3]Univ Elect Sci, Sichuan Prov Peoples Hosp, Sch Med, Chengdu, Sichuan, Peoples R China [4]Sino Japanese Friendship Hosp, Dept Nephrol, Beijing, Peoples R China [5]Zhejiang Univ, Affiliated Hosp 1, Dept Nephrol, Sch Med, Hangzhou, Zhejiang, Peoples R China [6]Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Nephrol, Sch Med, Shanghai, Peoples R China [7]Third Mil Med Univ, Dept Nephrol, Chongqing, Peoples R China [8]Guangdong Gen Hosp, Dept Nephrol, Guangzhou, Guangdong, Peoples R China
出处:
ISSN:

关键词: Chronic kidney disease Mineral and bone disorder Guideline China

摘要:
Chronic kidney disease (CKD) is a global health concern. The prevalence of CKD in Chinese adults is over 10%. Chronic kidney disease-mineral and bone disorder (CKD-MBD) is one of the complications of CKD, which may cause many serious adverse outcomes such as disability and death in CKD patients. In recent years, a series of guidelines for the diagnosis and treatment of CKD-MBD have been developed by several international organizations for kidney disease. In 2013, the working group developed the Guidance for Diagnosis and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder, which greatly promoted clinical management and researches of CKD-MBD in China. In the past five years, Chinese clinicians have been deepening their understanding and standardized management of CKD-MBD and implemented a large number of clinical and basic researches on CKD-MBD. In combination with international research results, the working group updated the guidelines. This guideline includes five chapters: introduction and definition of CKD-MBD; diagnosis of CKD-MBD; prevention and treatment of CKD-MBD; prevention and treatment of osteoporosis in patients with CKD; and evaluation and treatment of CKD-MBD in kidney transplant recipients; and five appendixes. In this summary, we highlight the main recommendations and suggestions of the guideline. (C) 2019 S. Karger AG, Basel

语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2018]版:
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 泌尿学与肾脏学
JCR分区:
出版当年[2017]版:
最新[2023]版:
Q1 UROLOGY & NEPHROLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2017版] 出版当年五年平均[2013-2017] 出版前一年[2016版]

第一作者:
第一作者单位: [1]Nanjing Gen Hosp, Natl Clin Res Ctr Kidney Dis, Dept Nephrol, Nanjing 210002, Jiangsu, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)